PMID- 29565004
OWN - NLM
STAT- MEDLINE
DCOM- 20181001
LR  - 20181202
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 391
IP  - 10125
DP  - 2018 Mar 17
TI  - End of the road for daclizumab in multiple sclerosis.
PG  - 1000
LID - S0140-6736(18)30565-8 [pii]
LID - 10.1016/S0140-6736(18)30565-8 [doi]
FAU - The Lancet
AU  - The Lancet
LA  - eng
PT  - Editorial
DEP - 20180315
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunosuppressive Agents)
RN  - CUJ2MVI71Y (Daclizumab)
SB  - AIM
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Daclizumab
MH  - *Drug Recalls
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Multiple Sclerosis/*drug therapy
EDAT- 2018/03/23 06:00
MHDA- 2018/10/03 06:00
CRDT- 2018/03/23 06:00
PHST- 2018/03/23 06:00 [entrez]
PHST- 2018/03/23 06:00 [pubmed]
PHST- 2018/10/03 06:00 [medline]
AID - S0140-6736(18)30565-8 [pii]
AID - 10.1016/S0140-6736(18)30565-8 [doi]
PST - ppublish
SO  - Lancet. 2018 Mar 17;391(10125):1000. doi: 10.1016/S0140-6736(18)30565-8. Epub
      2018 Mar 15.